A Phase 1 interventional study of DMB-3113 and Adalimumab in Healthy Volunteer, sponsored by Meiji Seika Pharma Co., Ltd.. Completed at 1 site in Japan. Open to male participants aged 20 Years to 39 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-08-22.
Sponsored by Meiji Seika Pharma Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To determine the pharmacokinetic bioequivalence of DMB-3113 and adalimumab and to confirm the safety of the study drug in healthy Japanese adult male subjects
Meiji Seika Pharma Co., Ltd. is the lead sponsor of 10 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
adalimumab biosimilar
Drug: DMB-3113
adalimumab
Drug: Adalimumab
subcutaneously injected in a single dose of 40 mg.
subcutaneously injected in a single dose of 40 mg.
Area under the serum concentration-time curve (AUC) from 0 to final sampling time point
Time frame: Day 1 to Day 71
AUC from 0 to infinity
Time frame: Day 1 to Day 71
Maximum serum concentration (Cmax)
Time frame: Day 1 to Day 71
AUC from 0 to the last measurable concentration
Time frame: Day 1 to Day 71
Time to reach the peak concentration (tmax)
Time frame: Day 1 to Day 71
Mean residence time (MRT) from 0 to final sampling time point
Time frame: Day 1 to Day 71
MRT from 0 to infinity
Time frame: Day 1 to Day 71
Elimination rate constant (kel)
Time frame: Day 1 to Day 71
Elimination half life (t1/2)
Time frame: Day 1 to Day 71
Observed clearance (CL/F)
Time frame: Day 1 to Day 71
Observed volume of distribution (V/F)
Time frame: Day 1 to Day 71
Incidence of adverse events
Time frame: Day 1 to Day 71
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Aug 2016, a primary completion of Jan 2017 and a completion of Jan 2017. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Meiji Seika Pharma Co., Ltd.